These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 33653729)

  • 21. Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives.
    Qiu H; Novikov A; Vallon V
    Diabetes Metab Res Rev; 2017 Jul; 33(5):. PubMed ID: 28099783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EUGLYCEMIC DIABETIC KETOACIDOSIS AND SEVERE ACUTE KIDNEY INJURY SECONDARY TO OFF LABEL USE OF SODIUM GLUCOSE COTRANSPORTER-2 INHIBITOR IN A TYPE-1 DIABETIC PATIENT.
    Tahir H; Wani A; Daruwalla V; Daboul N; Sagi J
    J Ayub Med Coll Abbottabad; 2015; 27(4):923-4. PubMed ID: 27004352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin.
    Bader N; Mirza L
    Pak J Med Sci; 2016; 32(3):786-8. PubMed ID: 27375734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SGLT2 Inhibitors May Predispose to Ketoacidosis.
    Taylor SI; Blau JE; Rother KI
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2849-52. PubMed ID: 26086329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data.
    Blau JE; Tella SH; Taylor SI; Rother KI
    Diabetes Metab Res Rev; 2017 Nov; 33(8):. PubMed ID: 28736981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ketoacidosis Due to Empagliflozin, a Paradigm Shift: Case Report and Review of Literature.
    Hernandez-Quiles C; Ramirez-Duque N; Acosta-Delgado D
    Curr Diabetes Rev; 2019; 15(4):259-262. PubMed ID: 30047331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diabetic ketoacidosis inducing myocardial infarction secondary to treatment with dapagliflozin: a case report.
    Gil-Perdomo JM; Fariña González TF; Jordán-Arias B; Domingo-Marín S; González Armengol JJ; Martínez-Sagasti F
    Clin Case Rep; 2017 Jun; 5(6):809-811. PubMed ID: 28588816
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Euglycemic Diabetic Ketoacidosis: A Review.
    Modi A; Agrawal A; Morgan F
    Curr Diabetes Rev; 2017; 13(3):315-321. PubMed ID: 27097605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SGLT-2 Inhibitors-a Culprit of Diabetic Ketoacidosis Postbariatric Surgery.
    Iqbal QZ; Mishiyev D; Niazi MR; Zia Z; Sattar SBA; Jahanghir A; Quyyumi S
    Case Rep Crit Care; 2020; 2020():8817829. PubMed ID: 33204542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission.
    Hamblin PS; Wong R; Ekinci EI; Fourlanos S; Shah S; Jones AR; Hare MJL; Calder GL; Epa DS; George EM; Giri R; Kotowicz MA; Kyi M; Lafontaine N; MacIsaac RJ; Nolan BJ; O'Neal DN; Renouf D; Varadarajan S; Wong J; Xu S; Bach LA
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3077-3087. PubMed ID: 30835263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol.
    Goldenberg RM; Gilbert JD; Hramiak IM; Woo VC; Zinman B
    Diabetes Obes Metab; 2019 Oct; 21(10):2192-2202. PubMed ID: 31183975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Acidosis without marked hyperglycemia : Euglycemic diabetic ketoacidosis associated with SGLT2-Inhibitors].
    Valek R; Von der Mark J
    Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):145-148. PubMed ID: 27221094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In HF, SGLT2 inhibitors reduce HF hospitalizations at up to 2 y.
    Brophy JM
    Ann Intern Med; 2022 Aug; 175(8):JC87. PubMed ID: 35914263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Euglycemic Diabetic Ketoacidosis Caused by a Sodium-glucose Co-transporter (SGLT) 2 Inhibitor after Coronary Artery Bypass Grafting].
    Kameda Y; Kato M; Inoue B; Yamazaki S; Sahara N; Aoki T; Nagashima Y; Nemoto N; Anzai H; Araki W; Kobayashi N
    Kyobu Geka; 2019 May; 72(5):354-357. PubMed ID: 31268032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Life-Threatening Complications Related to Delayed Diagnosis of Euglycemic Diabetic Ketoacidosis Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Report of 2 Cases.
    Goto S; Ishikawa JY; Idei M; Iwabuchi M; Namekawa M; Nomura T
    Am J Case Rep; 2021 Mar; 22():e929773. PubMed ID: 33723205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patients.
    Wang Y; Hu X; Liu X; Wang Z
    Ther Clin Risk Manag; 2016; 12():1113-31. PubMed ID: 27486328
    [TBL] [